Attracting EC Funding - Diana Salmen

Attracting EC Funding

The Human Variome Project

5th Biennial Meeting

19th-23rd May, 2014

Paris

Diana Salmen

Innovative and Personalised Medicine Unit

Health Research Directorate

DG Research & Innovation

Research and Innovation

HORIZON 2020

• The EU’s 2014-20 programme for research & innovation (around € 80 billion)

• A core part of Europe 2020, Innovation Union & European Research Area

• Three priorities: Excellent science, Industrial leadership, Societal challenges


Building on the FP7

experience…


FP7 'Health' – the largest

multi-national fund…

• …for collaborative research

• …to fund excellence

• …to bring together scientists

• …to tackle global challenges


Key figures

6 b€ invested to date

1,000 projects

11,000 teams

3,500 organisations

130 countries

First outcomes (on 329 closed projects = 1/3 of funded projects)

200 patent applications

9,000 publications

3,3 average SJR* publication

30 spin-offs created

* SCImago Journal Ranking


International K.O. Mouse Consortium

International Cancer Genomics

Consortium

International cooperation: Working on the big challenges

International Human Microbiome Consortium

Global Research Collaboration for Infectious Disease

Preparedness

International Rare Diseases Research

Consortium

International Initiative for Traumatic Brain

Injury Research

© rtg

uest/F

oto

lia.c

om

Global Alliance for Chronic Diseases

International Human Epigenome Consortium




Consortium




Preparedness


Consortium


Injury Research

© rtg

uest/F

oto

lia.c

om




www.irdirc.org

200 therapies

and means to

diagnose most rare disease by

2020


Basic principles

• Teams up public and private organisations investing in rare diseases research

• Research funders with relevant programmes >$10 million US over a 5-year period can join & work together

• Each organisation funds research its own way

• Funded projects adhere to a common framework

• Agree to share data / standards

Alignment – Flexibility - Commitment


Executive Committee Chair: Paul Lasko

Diagnostics

Chair: Kym Boycott

Interdisciplinary

Chair: Hanns Lochmueller

Therapies

Chair: Yann Le Cam

Scientific Committees

Working Groups

EU-funded SUPPORT-IRDiRC provides organisational support for Executive and Scientific Committees and Working Groups

Coordinator: Prof. Ségolène Aymé, INSERM

IRDiRC Governance Structure


IRDiRC timeline Exploratory Workshop Reykjavik

Launch Washington

Scientific Committees

Working Groups

IRDiRC 2013

Conference

3000 diagnostics

50 new applications for market

authorisation

Support-IRDiRC

Scientific Secretariat

6000 diagnostics

200 new applications for market

authorisation

2010 2011 2012 2013 2015 2020


Europe

E-RARE 2 Consortium (EU)

European Commission

EURORDIS (EU)

Academy of Finland

French Muscular Dystrophy Association

French National Research Agency

French Foundation for Rare Diseases

Children's New Hospitals Management Group (GE)

German Federal Ministry of Education and research

Italian Higher Institute of Health Research

Italian Telethon Foundation

Lysogene (FR)

Netherlands Organisation for Health Research and Development

Prosensa (NL)

Spanish Carlos III Health Institute

UK National Institute for Health Research

Committed members

© rtguest/Fotolia.com

Australia

National Health and Medical Research Council

Asia

BGI (CN)

Chinese Rare Disease Consortium

Korea National Institute of Health

North America

Canadian Institutes for Health Research

Genome Canada

FDA Orphan Products Grants Program

Genetic Alliance (US)

Genzyme (US)

Isis Pharmaceuticals (US)

Mendelian Disorders Genome Centres (US NIH)

National Centre for Translational Sciences (US NIH)

National Cancer Institute (US NIH)

National Institute of Neurological Disorders and Stroke (US NIH)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (US

NIH)

National Institute of Child Health and Human Development (US NIH)

National Eye Institute (US NIH)

NKT Therapeutics (US)

NORD (US)

Office of Rare Diseases (US NIH)

PTC Therapeutics (US)

Sanford Research (US)

Shire (US)




Consortium




Preparedness


Consortium


Injury Research

© rtg

uest/F

oto

lia.c

om




The International Human Epigenome Consortium (IHEC) is a global consortium with the primary goal of providing free access to high-resolution reference human epigenome maps for normal and disease cell types to the research

community.

EU

Germany

USA

Japan Korea

Canada

http://ihec-epigenomes.org/


At a Glance Generate reference maps of human epigenomes for key cellular states

relevant to health and disease. Ambitious goal to complete 1000 epigenomes

Rapid Data Release, Data Coordination, Archiving

Environment Disease Aging

Translation into Improved Human Health

Mechanism Prevention Diagnosis Therapy


IHEC Data


Horizon 2020

What's new?


• Challenge driven

• Broad topics

• Less prescriptive topics

• Two-year work programme

• Stronger focus on the end users


• Simplified eligibility criteria

• Simpler rules for grants

• Transparent funding rates

• New SME instrument

• Successful project running quicker


• Horizon 2020 is open

• Automatic funding

• Member States

• Associated countries

• Countries in Annex of the WP

• Exceptions


Horizon 2020 'Health, demographic

change and wellbeing'


• Ageing population

• Increased disease burden

• Unsustainable and unequal healthcare systems

• Healthcare sector under pressure to reform


• Translating science to benefit citizens

• Improve health outcomes

• Support a competitive healthcare sector

• Test and demonstrate new healthcare models, approaches and tools

• Promote healthy and active ageing

The Work Programme 2014 - 2015

Call for 'co-ordination activities' 16 topics (11 in 2014, 5 in 2015)

Call 'personalising health and care' 34 topics (15 in 2014, 17 in 2015, 2 open in both years)

+ 8 other actions not subject to calls for proposals

Research & Innovation

EU funding for health research and innovation 2014-2015


Understanding

health, ageing &

disease

Improving health

information, data

exploitation and

providing an evidence

base for health policies

and regulation

Integrated,

sustainable,

citizen-centered

care

Innovative

treatments and

technologies

Improving

diagnosis

Implementing personalized medicine in healthcare settings

Effective health

promotion, disease

prevention,

preparedness and

screening

Advancing active

and healthy aging




http://ec.europa.eu/research/participants/portal

Participant Portal– your one-stop shop


Thank you

[email protected]

http://ec.europa.eu/research/health

http://ec.europa.eu/programmes/horizon2020